双歧杆菌乳杆菌三联活菌片对慢传输型便秘大鼠肠道Cajal间质细胞增殖的影响  

Effect of live combined bifidobacterium and lactobacillus tablets on intestinal Cajal interstitial cell proliferation with slow transit constipation in rats

作　　者：刘丽雅 张欣然[1] 吴与伦 刘启鸿 陈锦团[1] 谢秋容 魏丽慧 柯晓 沈阿灵[1] LIU Liya;ZHANG Xinran;WU Yulun;LIU Qihong;CHEN Jintuan;XIE Qiurong;WEI Lihui;KE Xiao;SHEN Aling(Academy of Integrative Medicine,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,Fujian,China;Affiliated Sanming Integrated Medicine Hospital of Fujian University of Traditional Chinese Medicine,Sanming 353001,Fujian,China;Department of Spleen and Stomach,the Second People’s Hospital,Fujian University of Traditional Chinese Medicine,Fuzhou 350003,Fujian,China;Fujian Traditional Chinese Medicine Spleen and Stomach Clinical Medical Research Center,Fuzhou 350003,Fujian,China;Innovation and Transformation Center,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,Fujian,China)

机构地区：[1]福建中医药大学中西医结合研究院,福建福州350122 [2]福建中医药大学附属三明中西医结合医院,福建三明365001 [3]福建中医药大学附属第二人民医院脾胃病科,福建福州350003 [4]福建省中医脾胃临床医学研究中心,福建福州350003 [5]福建中医药大学科技创新与转化中心,福建福州350122

出　　处：《中国现代医生》2024年第35期72-77,83,共7页China Modern Doctor

基　　金：内蒙古双奇药业股份有限公司横向课题(HX2022001)。

摘　　要：目的探讨双歧杆菌乳杆菌三联活菌片对慢传输型便秘(slow transit constipation,STC)大鼠的治疗作用及相关机制。方法SPF级Wistar成年雌性大鼠30只,采用随机数字表法分为对照组、模型组、双歧杆菌乳杆菌三联活菌片低剂量组(0.270g/kg)、双歧杆菌乳杆菌三联活菌片中剂量组(0.540g/kg)、双歧杆菌乳杆菌三联活菌片高剂量组(1.080g/kg)、阳性药(琥珀酸普芦卡必利片)(0.180mg/kg)组,每组5只。采用盐酸洛哌丁胺灌胃建立STC大鼠模型。造模成功后,在继续造模的基础上分别给予药物灌胃,连续给药14d。观察并计算各组大鼠一般体征变化、粪便含水率及肠道推进率,采用HE染色观察结肠组织病理学改变。采用免疫组织化学法检测大鼠结肠组织中受体酪氨酸激酶(receptor tyrosine kinase,c-Kit),5-羟色胺(5-hydroxytryptamine,5-HT),5-HT3受体(5-hydroxy tryptamine 3 receptor,5-HT3R)和5-HT4受体(5-hydroxy tryptamine 4 receptor,5-HT4R)的蛋白表达。结果与对照组比较,模型组大鼠的排便次数、粪便含水量、肠道推进速度等均有所下降,大鼠肠组织中c-Kit、5-HT、5-HT3R、5-HT4R等蛋白表达水平均明显降低(P<0.05)。与模型组比较,给予双歧杆菌乳杆菌三联活菌片干预后,双歧杆菌乳杆菌三联活菌片低、中、高剂量组大鼠排便频率、粪便含水率、肠道推进率、肠组织中c-Kit,5-HT,5-HT3R和5-HT4R的蛋白表达均明显升高(P<0.05)。结论肠道益生菌制剂双歧杆菌乳杆菌三联活菌片可有效改善STC的作用,通过促进结肠Cajal间质细胞增殖、增加5-HT、5-HT3R、5-HT4R的蛋白表达,可能是双歧杆菌乳杆菌三联活菌片改善STC的重要作用机制之一。Objective To investigate the therapeutic effect and mechanisms of live combined bifidobacterium and lactobacillus tablets on slow transit constipation(STC)rats.Methods A total of 30 SPF grade Wistar adult female rats were blinded and divided into control group,model group,live combined bifidobacterium and lactobacillus tablets low-dose(0.270g/kg),live combined bifidobacterium and lactobacillus tablets medium dose group(0.540g/kg),live combined bifidobacterium and lactobacillus tablets high-dose group(1.080g/kg),and positive drug group(prucalopride succinate tablet)(0.180mg/kg),with 5 rats in each group.A rat model of STC was established by gavage of loperamide hydrochloride.After successful modeling,medication was administered by gavage for 14 consecutive days on the basis of continued modeling.Observe the changes in general physical signs,fecal water content,and calculate intestinal motility in each group of rats.Using HE staining to observe pathological changes in colon tissue,immunohistochemical methods were used to detect the protein expression of receptor tyrosine kinase(c-Kit),5-hydroxytryptamine(5-HT),5-hydroxytryptamine 3 receptor(5-HT3R),and 5-hydroxytryptamine 4 receptor(5-HT4R)in rat colon tissue.Results Compared with control group,frequency of defecation,fecal water content and intestinal propulsion speed of STC model rats were significantly decreased.The expression levels of proteins such as c-Kit,5-HT,5-HT3R,and 5-HT4R in intestinal tissues were significantly reduced in STC model rats.Compared with STC model group,rats treated with low,medium and high doses of live combined bifidobacterium and lactobacillus tablets and positive drug groups showed a significant increase in bowel frequency,fecal water content,and intestinal motility after intervention.Compared with STC model group,frequency of defecation,fecal water content,intestinal propulsion rate and protein expression of c-Kit,5-HT,5-HT3R and 5-HT4R in rat intestinal tissues were significantly increased after intervention of live combined bifidob

关 键 词：慢传输型便秘 5-羟色胺 CAJAL间质细胞 

分 类 号：R574.8[医药卫生—消化系统]